Robert V. Market

Mr. Market is an Assistant Director in the Wafic Said Molecular Cardiology Research Laboratories at the Texas Heart Institute and Intellectual Property Manager for the Office of Research Administration. He has over 20 years of drug discovery experience. He is also licensed to practice law in the State of Texas and before the USPTO. Currently, he also aids in the prosecution of patent applications generated through the institute.

See Publications

Texas Heart Institute Positions

Interests

  • Non-invasive diagnostic imaging technologies

Publications

4862227 5QIRWFUY 1 alternatives-to-animal-experimentation 10 date desc Market 1992 https://www.texasheart.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22I7XSBSGG%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hickman%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHickman%2C%20A.%2C%20Koetsier%2C%20J.%2C%20Kurtanich%2C%20T.%20et%20al.%20%282022%29.%20LFA-1%20activation%20enriches%20tumor-specific%20T%20cells%20in%20a%20cold%20tumor%20model%20and%20synergizes%20with%20CTLA-4%20blockade.%20%26lt%3Bi%26gt%3BJ%20Clin%20Invest%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B132%26lt%3B%5C%2Fi%26gt%3B%2C%20e154152.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1172%5C%2FJCI154152%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1172%5C%2FJCI154152%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22LFA-1%20activation%20enriches%20tumor-specific%20T%20cells%20in%20a%20cold%20tumor%20model%20and%20synergizes%20with%20CTLA-4%20blockade%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amber%22%2C%22lastName%22%3A%22Hickman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joost%22%2C%22lastName%22%3A%22Koetsier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Trevin%22%2C%22lastName%22%3A%22Kurtanich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20C.%22%2C%22lastName%22%3A%22Nielsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Glenn%22%2C%22lastName%22%3A%22Winn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yunfei%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salah-Eddine%22%2C%22lastName%22%3A%22Bentebibel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leilei%22%2C%22lastName%22%3A%22Shi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Punt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leila%22%2C%22lastName%22%3A%22Williams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cara%22%2C%22lastName%22%3A%22Haymaker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20B.%22%2C%22lastName%22%3A%22Chesson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faisal%22%2C%22lastName%22%3A%22Fa%27ak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%20L.%22%2C%22lastName%22%3A%22Dominguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Jones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isere%22%2C%22lastName%22%3A%22Kuiatse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%20R.%22%2C%22lastName%22%3A%22Caivano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sayadeth%22%2C%22lastName%22%3A%22Khounlo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Navin%20D.%22%2C%22lastName%22%3A%22Warier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Upendra%22%2C%22lastName%22%3A%22Marathi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20V.%22%2C%22lastName%22%3A%22Market%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20J.%22%2C%22lastName%22%3A%22Biediger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20W.%22%2C%22lastName%22%3A%22Craft%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Hwu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20G.%22%2C%22lastName%22%3A%22Woodside%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Vanderslice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adi%22%2C%22lastName%22%3A%22Diab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Willem%20W.%22%2C%22lastName%22%3A%22Overwijk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yared%22%2C%22lastName%22%3A%22Hailemichael%22%7D%5D%2C%22abstractNote%22%3A%22The%20inability%20of%20CD8%2B%20effector%20T%20cells%20%28Teffs%29%20to%20reach%20tumor%20cells%20is%20an%20important%20aspect%20of%20tumor%20resistance%20to%20cancer%20immunotherapy.%20The%20recruitment%20of%20these%20cells%20to%20the%20tumor%20microenvironment%20%28TME%29%20is%20regulated%20by%20integrins%2C%20a%20family%20of%20adhesion%20molecules%20that%20are%20expressed%20on%20T%20cells.%20Here%2C%20we%20show%20that%207HP349%2C%20a%20small-molecule%20activator%20of%20lymphocyte%20function-associated%20antigen-1%20%28LFA-1%29%20and%20very%20late%20activation%20antigen-4%20%28VLA-4%29%20integrin%20cell-adhesion%20receptors%2C%20facilitated%20the%20preferential%20localization%20of%20tumor-specific%20T%20cells%20to%20the%20tumor%20and%20improved%20antitumor%20response.%207HP349%20monotherapy%20had%20modest%20effects%20on%20anti-programmed%20death%201-resistant%20%28anti-PD-1-resistant%29%20tumors%2C%20whereas%20combinatorial%20treatment%20with%20anti-cytotoxic%20T%20lymphocyte-associated%20protein%204%20%28anti-CTLA-4%29%20increased%20CD8%2B%20Teff%20intratumoral%20sequestration%20and%20synergized%20in%20cooperation%20with%20neutrophils%20in%20inducing%20cancer%20regression.%207HP349%20intratumoral%20CD8%2B%20Teff%20enrichment%20activity%20depended%20on%20CXCL12.%20We%20analyzed%20gene%20expression%20profiles%20using%20RNA%20from%20baseline%20and%20on%20treatment%20tumor%20samples%20of%2014%20melanoma%20patients.%20We%20identified%20baseline%20CXCL12%20gene%20expression%20as%20possibly%20improving%20the%20likelihood%20or%20response%20to%20anti-CTLA-4%20therapies.%20Our%20results%20provide%20a%20proof-of-principle%20demonstration%20that%20LFA-1%20activation%20could%20convert%20a%20T%20cell-exclusionary%20TME%20to%20a%20T%20cell-enriched%20TME%20through%20mechanisms%20involving%20cooperation%20with%20innate%20immune%20cells.%22%2C%22date%22%3A%22July%2001%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1172%5C%2FJCI154152%22%2C%22ISSN%22%3A%221558-8238%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226MADD4J5%22%2C%22BBMMGS3D%22%2C%227XFQVVGN%22%2C%224R4R39JD%22%2C%227STYFUFZ%22%2C%225QIRWFUY%22%2C%22TC3LQMP8%22%2C%222RCWVZ4F%22%5D%2C%22dateModified%22%3A%222022-08-02T14%3A41%3A07Z%22%7D%7D%2C%7B%22key%22%3A%227TUX9HBZ%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lokugamage%20et%20al.%22%2C%22parsedDate%22%3A%222021-09-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLokugamage%2C%20N.%2C%20Chowdhury%2C%20I.%20H.%2C%20Biediger%2C%20R.%20J.%20et%20al.%20%282021%29.%20Use%20of%20a%20small%20molecule%20integrin%20activator%20as%20a%20systemically%20administered%20vaccine%20adjuvant%20in%20controlling%20Chagas%20disease.%20%26lt%3Bi%26gt%3BNPJ%20Vaccines%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B6%26lt%3B%5C%2Fi%26gt%3B%2C%20114.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41541-021-00378-5%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41541-021-00378-5%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Use%20of%20a%20small%20molecule%20integrin%20activator%20as%20a%20systemically%20administered%20vaccine%20adjuvant%20in%20controlling%20Chagas%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nandadeva%22%2C%22lastName%22%3A%22Lokugamage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Imran%20H.%22%2C%22lastName%22%3A%22Chowdhury%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20J.%22%2C%22lastName%22%3A%22Biediger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20V.%22%2C%22lastName%22%3A%22Market%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sayadeth%22%2C%22lastName%22%3A%22Khounlo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Navin%20D.%22%2C%22lastName%22%3A%22Warier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shen-An%22%2C%22lastName%22%3A%22Hwang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20K.%22%2C%22lastName%22%3A%22Actor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20G.%22%2C%22lastName%22%3A%22Woodside%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Upendra%22%2C%22lastName%22%3A%22Marathi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Vanderslice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nisha%20Jain%22%2C%22lastName%22%3A%22Garg%22%7D%5D%2C%22abstractNote%22%3A%22The%20development%20of%20suitable%20safe%20adjuvants%20to%20enhance%20appropriate%20antigen-driven%20immune%20responses%20remains%20a%20challenge.%20Here%20we%20describe%20the%20adjuvant%20properties%20of%20a%20small%20molecule%20activator%20of%20the%20integrins%20%5Cu03b1L%5Cu03b22%20and%20%5Cu03b14%5Cu03b21%2C%20named%207HP349%2C%20which%20can%20be%20safely%20delivered%20systemically%20independent%20of%20antigen.%207HP349%20directly%20activates%20integrin%20cell%20adhesion%20receptors%20crucial%20for%20the%20generation%20of%20an%20immune%20response.%20When%20delivered%20systemically%20in%20a%20model%20of%20Chagas%20disease%20following%20immunization%20with%20a%20DNA%20subunit%20vaccine%20encoding%20candidate%20T.%20cruzi%20antigens%2C%20TcG2%20and%20TcG4%2C%207HP349%20enhanced%20the%20vaccine%20efficacy%20in%20both%20prophylactic%20and%20therapeutic%20settings.%20In%20a%20prophylactic%20setting%2C%20mice%20immunized%20with%207HP349%20adjuvanted%20vaccine%20exhibited%20significantly%20improved%20control%20of%20acute%20parasite%20burden%20in%20cardiac%20and%20skeletal%20muscle%20as%20compared%20to%20vaccination%20alone.%20When%20administered%20with%20vaccine%20therapeutically%2C%20parasite%20burden%20was%20again%20decreased%2C%20with%20the%20greatest%20adjuvant%20effect%20of%207HP349%20being%20noted%20in%20skeletal%20muscle.%20In%20both%20settings%2C%20adjuvantation%20with%207HP349%20was%20effective%20in%20decreasing%20pathological%20inflammatory%20infiltrate%2C%20improving%20the%20integrity%20of%20tissue%2C%20and%20controlling%20tissue%20fibrosis%20in%20the%20heart%20and%20skeletal%20muscle%20of%20acutely%20and%20chronically%20infected%20Chagas%20mice.%20The%20positive%20effects%20correlated%20with%20increased%20splenic%20frequencies%20of%20CD8%2BT%20effector%20cells%20and%20an%20increase%20in%20the%20production%20of%20IFN-%5Cu03b3%20and%20cytolytic%20molecules%20%28perforin%20and%20granzyme%29%20by%20the%20CD4%2B%20and%20CD8%2B%20effector%20and%20central%20memory%20subsets%20in%20response%20to%20challenge%20infection.%20This%20demonstrates%20that%207HP349%20can%20serve%20as%20a%20systemically%20administered%20adjuvant%20to%20enhance%20T%20cell-mediated%20immune%20responses%20to%20vaccines.%20This%20approach%20could%20be%20applied%20to%20numerous%20vaccines%20with%20no%20reformulation%20of%20existing%20stockpiles.%22%2C%22date%22%3A%22Sept%2008%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41541-021-00378-5%22%2C%22ISSN%22%3A%222059-0105%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226MADD4J5%22%2C%22BBMMGS3D%22%2C%227XFQVVGN%22%2C%227STYFUFZ%22%2C%225QIRWFUY%22%2C%22TC3LQMP8%22%5D%2C%22dateModified%22%3A%222021-10-07T18%3A11%3A58Z%22%7D%7D%2C%7B%22key%22%3A%229LRIQ9XJ%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Woodside%20et%20al.%22%2C%22parsedDate%22%3A%222018-02-27%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BWoodside%2C%20D.%20G.%2C%20Tanifum%2C%20E.%20A.%2C%20Ghaghada%2C%20K.%20B.%20et%20al.%20%282018%29.%20Magnetic%20resonance%20imaging%20of%20atherosclerotic%20plaque%20at%20clinically%20relevant%20field%20strengths%20%281T%29%20by%20targeting%20the%20integrin%20%26%23x3B1%3B4%26%23x3B2%3B1.%20%26lt%3Bi%26gt%3BSci%20Rep%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B8%26lt%3B%5C%2Fi%26gt%3B%2C%203733.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-018-21893-x%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-018-21893-x%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Magnetic%20resonance%20imaging%20of%20atherosclerotic%20plaque%20at%20clinically%20relevant%20field%20strengths%20%281T%29%20by%20targeting%20the%20integrin%20%5Cu03b14%5Cu03b21%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20G.%22%2C%22lastName%22%3A%22Woodside%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%20A.%22%2C%22lastName%22%3A%22Tanifum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ketan%20B.%22%2C%22lastName%22%3A%22Ghaghada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20J.%22%2C%22lastName%22%3A%22Biediger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%20R.%22%2C%22lastName%22%3A%22Caivano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zbigniew%20A.%22%2C%22lastName%22%3A%22Starosolski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sayadeth%22%2C%22lastName%22%3A%22Khounlo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saakshi%22%2C%22lastName%22%3A%22Bhayana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shahrzad%22%2C%22lastName%22%3A%22Abbasi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20W.%22%2C%22lastName%22%3A%22Craft%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20S.%22%2C%22lastName%22%3A%22Maxwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chandreshkumar%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Igor%20V.%22%2C%22lastName%22%3A%22Stupin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deenadayalan%22%2C%22lastName%22%3A%22Bakthavatsalam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20V.%22%2C%22lastName%22%3A%22Market%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20T.%22%2C%22lastName%22%3A%22Willerson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%20F.%22%2C%22lastName%22%3A%22Dixon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Vanderslice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ananth%20V.%22%2C%22lastName%22%3A%22Annapragada%22%7D%5D%2C%22abstractNote%22%3A%22Inflammation%20drives%20the%20degradation%20of%20atherosclerotic%20plaque%2C%20yet%20there%20are%20no%20non-invasive%20techniques%20available%20for%20imaging%20overall%20inflammation%20in%20atherosclerotic%20plaques%2C%20especially%20in%20the%20coronary%20arteries.%20To%20address%20this%2C%20we%20have%20developed%20a%20clinically%20relevant%20system%20to%20image%20overall%20inflammatory%20cell%20burden%20in%20plaque.%20Here%2C%20we%20describe%20a%20targeted%20contrast%20agent%20%28THI0567-targeted%20liposomal-Gd%29%20that%20is%20suitable%20for%20magnetic%20resonance%20%28MR%29%20imaging%20and%20binds%20with%20high%20affinity%20and%20selectivity%20to%20the%20integrin%20%5Cu03b14%5Cu03b21%28very%20late%20antigen-4%2C%20VLA-4%29%2C%20a%20key%20integrin%20involved%20in%20recruiting%20inflammatory%20cells%20to%20atherosclerotic%20plaques.%20This%20liposomal%20contrast%20agent%20has%20a%20high%20T1%20relaxivity%20%28~2%5Cu2009%5Cu00d7%5Cu2009105%5Cu2009mM-1s-1%20on%20a%20particle%20basis%29%20resulting%20in%20the%20ability%20to%20image%20liposomes%20at%20a%20clinically%20relevant%20MR%20field%20strength.%20We%20were%20able%20to%20visualize%20atherosclerotic%20plaques%20in%20various%20regions%20of%20the%20aorta%20in%20atherosclerosis-prone%20ApoE-%5C%2F-%20mice%20on%20a%201%20Tesla%20small%20animal%20MRI%20scanner.%20These%20enhanced%20signals%20corresponded%20to%20the%20accumulation%20of%20monocyte%5C%2Fmacrophages%20in%20the%20subendothelial%20layer%20of%20atherosclerotic%20plaques%20in%20vivo%2C%20whereas%20non-targeted%20liposomal%20nanoparticles%20did%20not%20demonstrate%20comparable%20signal%20enhancement.%20An%20inflammatory%20cell-targeted%20method%20that%20has%20the%20specificity%20and%20sensitivity%20to%20measure%20the%20inflammatory%20burden%20of%20a%20plaque%20could%20be%20used%20to%20noninvasively%20identify%20patients%20at%20risk%20of%20an%20acute%20ischemic%20event.%22%2C%22date%22%3A%22Feb%2027%2C%202018%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-018-21893-x%22%2C%22ISSN%22%3A%222045-2322%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NNUFWYNJ%22%2C%226MADD4J5%22%2C%22WGZKEVDQ%22%2C%22BBMMGS3D%22%2C%227XFQVVGN%22%2C%22JH9V95Q8%22%2C%22VXDM6BAE%22%2C%224R4R39JD%22%2C%227STYFUFZ%22%2C%225QIRWFUY%22%5D%2C%22dateModified%22%3A%222018-05-07T19%3A32%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22MAGUF57R%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wu%20et%20al.%22%2C%22parsedDate%22%3A%221999-11-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BWu%2C%20C.%2C%20Decker%2C%20E.%20R.%2C%20Blok%2C%20N.%20et%20al.%20%281999%29.%20Endothelin%20antagonists%3A%20substituted%20mesitylcarboxamides%20with%20high%20potency%20and%20selectivity%20for%20ET%28A%29%20receptors.%20%26lt%3Bi%26gt%3BJ%20Med%20Chem%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B42%26lt%3B%5C%2Fi%26gt%3B%2C%204485%26%23x2013%3B4499%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Endothelin%20antagonists%3A%20substituted%20mesitylcarboxamides%20with%20high%20potency%20and%20selectivity%20for%20ET%28A%29%20receptors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20R.%22%2C%22lastName%22%3A%22Decker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Blok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Bui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Q.%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Raju%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20R.%22%2C%22lastName%22%3A%22Bourgoyne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Knowles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20J.%22%2C%22lastName%22%3A%22Biediger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20V.%22%2C%22lastName%22%3A%22Market%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Lin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Dupr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20P.%22%2C%22lastName%22%3A%22Kogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20W.%22%2C%22lastName%22%3A%22Holland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20A.%22%2C%22lastName%22%3A%22Brock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20A.%22%2C%22lastName%22%3A%22Dixon%22%7D%5D%2C%22abstractNote%22%3A%22We%20have%20previously%20disclosed%20the%20discovery%20of%202%2C4-disubstituted%20anilinothiophenesulfonamides%20with%20potent%20ET%28A%29-selective%20endothelin%20receptor%20antagonism%20and%20the%20subsequent%20identification%20of%20sitaxsentan%20%28TBC11251%2C%201%29%20as%20a%20clinical%20development%20compound%20%28Wu%20et%20al.%20J.%20Med.%20Chem.%201997%2C%2040%2C%201682%20and%201690%29.%20The%20orally%20active%201%20has%20demonstrated%20efficacy%20in%20a%20phase%20II%20clinical%20trial%20of%20congestive%20heart%20failure%20%28Givertz%20et%20al.%20Circulation%201998%2C%2098%2C%20Abstr.%20%233044%29%20and%20was%20active%20in%20rat%20models%20of%20myocardial%20infarction%20%28Podesser%20et%20al.%20Circulation%201998%2C%2098%2C%20Abstr.%20%232896%29%20and%20acute%20hypoxia-induced%20pulmonary%20hypertension%20%28Chen%20et%20al.%20FASEB%20J.%201996%2C%2010%20%283%29%2C%20A104%29.%20We%20now%20report%20that%20an%20additional%20substituent%20at%20the%206-position%20of%20the%20anilino%20ring%20further%20increases%20the%20potency%20of%20this%20series%20of%20compounds.%20It%20was%20also%20found%20that%20a%20wide%20range%20of%20functionalities%20at%20the%203-position%20of%20the%202%2C4%2C6-trisubstituted%20ring%20increased%20ET%28A%29%20selectivity%20by%20approximately%2010-fold%20while%20maintaining%20in%20vitro%20potency%2C%20therefore%20rendering%20the%20compounds%20amenable%20to%20fine-tuning%20of%20pharmacological%20and%20toxicological%20profiles%20with%20enhanced%20selectivity.%20The%20optimal%20compound%20in%20this%20series%20was%20found%20to%20be%20TBC2576%20%287u%29%2C%20which%20has%20approximately%2010-fold%20higher%20ET%28A%29%20binding%20affinity%20than%201%2C%20high%20ET%28A%29%5C%2FET%28B%29%20selectivity%2C%20and%20a%20serum%20half-life%20of%207.3%20h%20in%20rats%2C%20as%20well%20as%20in%20vivo%20activity.%22%2C%22date%22%3A%22Nov%2004%2C%201999%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%220022-2623%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%225QIRWFUY%22%5D%2C%22dateModified%22%3A%222018-06-04T16%3A06%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22Y2S4YVEG%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Scott%20et%20al.%22%2C%22parsedDate%22%3A%221999%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BScott%2C%20I.%20L.%2C%20%26lt%3Bstrong%26gt%3BMarket%26lt%3B%5C%2Fstrong%26gt%3B%2C%20R.%20V.%2C%20DeOrazio%2C%20R.%20J.%20et%20al.%20%281999%29.%20Stereospecific%20%26%23x3B1%3B-d-mannosylation.%20%26lt%3Bi%26gt%3BCarbohydrate%20Research%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B317%26lt%3B%5C%2Fi%26gt%3B%2C%20210%26%23x2013%3B216.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS0008-6215%2899%2900065-8%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS0008-6215%2899%2900065-8%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Stereospecific%20%5Cu03b1-d-mannosylation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%20L.%22%2C%22lastName%22%3A%22Scott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20V.%22%2C%22lastName%22%3A%22Market%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Russell%20J.%22%2C%22lastName%22%3A%22DeOrazio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harold%22%2C%22lastName%22%3A%22Meckler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20P.%22%2C%22lastName%22%3A%22Kogan%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2204%5C%2F1999%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2FS0008-6215%2899%2900065-8%22%2C%22ISSN%22%3A%2200086215%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS0008621599000658%22%2C%22collections%22%3A%5B%225QIRWFUY%22%5D%2C%22dateModified%22%3A%222018-06-04T15%3A51%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22XBKJNHJ8%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dupr%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%221996%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDupr%26%23xE9%3B%2C%20B.%2C%20Bui%2C%20H.%2C%20Scott%2C%20I.%20L.%20et%20al.%20%281996%29.%20Glycomimetic%20selectin%20inhibitors%3A%20%28%26%23x3B1%3B-D-mannopyranosyloxy%29methylbiphenyls.%20%26lt%3Bi%26gt%3BBioorganic%20%26amp%3B%20Medicinal%20Chemistry%20Letters%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B6%26lt%3B%5C%2Fi%26gt%3B%2C%20569%26%23x2013%3B572.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2F0960-894X%2896%2900071-6%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2F0960-894X%2896%2900071-6%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Glycomimetic%20selectin%20inhibitors%3A%20%28%5Cu03b1-D-mannopyranosyloxy%29methylbiphenyls%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%22%2C%22lastName%22%3A%22Dupr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Huong%22%2C%22lastName%22%3A%22Bui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%20L.%22%2C%22lastName%22%3A%22Scott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20V.%22%2C%22lastName%22%3A%22Market%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karin%20M.%22%2C%22lastName%22%3A%22Keller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pamela%20J.%22%2C%22lastName%22%3A%22Beck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20P.%22%2C%22lastName%22%3A%22Kogan%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%223%5C%2F1996%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2F0960-894X%2896%2900071-6%22%2C%22ISSN%22%3A%220960894X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2F0960894X96000716%22%2C%22collections%22%3A%5B%225QIRWFUY%22%5D%2C%22dateModified%22%3A%222018-06-04T15%3A51%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22E3GPU77M%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kogan%20et%20al.%22%2C%22parsedDate%22%3A%221995-12-22%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKogan%2C%20T.%20P.%2C%20Dupr%26%23xE9%3B%2C%20B.%2C%20Keller%2C%20K.%20M.%20et%20al.%20%281995%29.%20Rational%20design%20and%20synthesis%20of%20small%20molecule%2C%20non-oligosaccharide%20selectin%20inhibitors%3A%20%28%26%23x3B1%3B-D-mannopyranosyloxy%29biphenyl-substituted%20carboxylic%20acids.%20%26lt%3Bi%26gt%3BJ%20Med%20Chem%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B38%26lt%3B%5C%2Fi%26gt%3B%2C%204976%26%23x2013%3B4984%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rational%20design%20and%20synthesis%20of%20small%20molecule%2C%20non-oligosaccharide%20selectin%20inhibitors%3A%20%28%5Cu03b1-D-mannopyranosyloxy%29biphenyl-substituted%20carboxylic%20acids%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20P.%22%2C%22lastName%22%3A%22Kogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Dupr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20M.%22%2C%22lastName%22%3A%22Keller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%20L.%22%2C%22lastName%22%3A%22Scott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Bui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20V.%22%2C%22lastName%22%3A%22Market%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20J.%22%2C%22lastName%22%3A%22Beck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20A.%22%2C%22lastName%22%3A%22Voytus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20M.%22%2C%22lastName%22%3A%22Revelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Scott%22%7D%5D%2C%22abstractNote%22%3A%22The%20calcium%20dependent%20E-selectin%5C%2Fsialyl%20Lewisx%20%28sLex%29%20interaction%20plays%20a%20key%20role%20in%20inflammation%20where%20it%20mediates%20the%20rolling%20of%20leukocytes%20prior%20to%20firm%20adhesion%20and%20extravasation%20from%20the%20vasculature.%20A%20model%20of%20E-selectin%5C%2FsLex%20binding%2C%20along%20with%20previously%20reported%20structure-activity%20relationships%20of%20sLex-related%20oligosaccharide%2C%20was%20used%20in%20the%20rational%20design%20of%20non-oligosaccharide%20inhibitors%20of%20this%20pivotal%20interaction.%20A%20palladium-mediated%20biaryl-coupling%20%28Suzuki%29%20reaction%20was%20used%20as%20the%20key%20step%20to%20prepare%20a%20number%20of%20substituted%20biphenyls%20which%20were%20assayed%20for%20their%20ability%20to%20inhibit%20the%20binding%20of%20E-%2C%20P-%2C%20and%20L-selectin-IgG%20fusion%20proteins%20to%20sLex%20expressed%20on%20the%20surface%20of%20HL60%20cells.%20Some%20of%20the%20compounds%20developed%20had%20greater%20in%20vitro%20potency%20than%20the%20parent%20sLex%20tetrasaccharide%20and%20are%20currently%20being%20evaluated%20in%20in%20vivo%20models%20of%20inflammation%20to%20select%20a%20candidate%20for%20clinical%20development.%22%2C%22date%22%3A%22Dec%2022%2C%201995%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%220022-2623%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%225QIRWFUY%22%5D%2C%22dateModified%22%3A%222019-01-07T17%3A38%3A27Z%22%7D%7D%5D%7D
Hickman, A., Koetsier, J., Kurtanich, T. et al. (2022). LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. J Clin Invest 132, e154152. https://doi.org/10.1172/JCI154152.
Lokugamage, N., Chowdhury, I. H., Biediger, R. J. et al. (2021). Use of a small molecule integrin activator as a systemically administered vaccine adjuvant in controlling Chagas disease. NPJ Vaccines 6, 114. https://doi.org/10.1038/s41541-021-00378-5.
Woodside, D. G., Tanifum, E. A., Ghaghada, K. B. et al. (2018). Magnetic resonance imaging of atherosclerotic plaque at clinically relevant field strengths (1T) by targeting the integrin α4β1. Sci Rep 8, 3733. https://doi.org/10.1038/s41598-018-21893-x.
Wu, C., Decker, E. R., Blok, N. et al. (1999). Endothelin antagonists: substituted mesitylcarboxamides with high potency and selectivity for ET(A) receptors. J Med Chem 42, 4485–4499
Scott, I. L., Market, R. V., DeOrazio, R. J. et al. (1999). Stereospecific α-d-mannosylation. Carbohydrate Research 317, 210–216. https://doi.org/10.1016/S0008-6215(99)00065-8.
Dupré, B., Bui, H., Scott, I. L. et al. (1996). Glycomimetic selectin inhibitors: (α-D-mannopyranosyloxy)methylbiphenyls. Bioorganic & Medicinal Chemistry Letters 6, 569–572. https://doi.org/10.1016/0960-894X(96)00071-6.
Kogan, T. P., Dupré, B., Keller, K. M. et al. (1995). Rational design and synthesis of small molecule, non-oligosaccharide selectin inhibitors: (α-D-mannopyranosyloxy)biphenyl-substituted carboxylic acids. J Med Chem 38, 4976–4984

Recent News

Texas Heart Institute’s molecular discovery at the heart of a new vaccine development program

A promising molecular technology co-invented by scientists at the Texas Heart Institute and 7 Hills could soon enhance the effectiveness...

Texas Heart Institute Discovery to Enhance the Immune System Moves Closer to Clinical Testing

A promising technology invented at the Texas Heart Institute is one step closer to being tested in a clinical study...